A Phase I, Open-Label, Two-Part, Multicenter Perjeta Subcutaneous Dose-Finding Study in Combination With Herceptin in Healthy Male Volunteers and Female Patients With Early Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 17 May 2017
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Pharmacokinetics
- Sponsors Roche
- 10 Mar 2017 Planned End Date changed from 1 Sep 2017 to 15 Aug 2018.
- 10 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 15 Aug 2018.
- 01 Jul 2016 Status changed from not yet recruiting to recruiting.